A major update to NHS weight loss jabs could change how patients receive treatment, after regulators approved a higher-dose version of the widely used drug Wegovy.
The Medicines and Healthcare products Regulatory Agency has authorised a new single-dose 7.2mg semaglutide pen, designed for adults with obesity.
The move means eligible patients may now be able to take their full weekly dose in just one injection, rather than multiple doses.
Previously, patients needing the highest 7.2mg dose had to take three separate 2.4mg injections on the same day. The newly approved pen simplifies this into a single weekly jab.
Who is eligible for weight loss jabs on the NHS?
The decision is expected to support weight loss and weight management for adults with a Body Mass Index of 30 or above, a key threshold for NHS obesity treatment.
Officials say the change could make treatment easier and more convenient, particularly for those already using NHS weight loss jabs as part of a wider obesity care plan.
However, the approval does not apply to people who are overweight but do not meet the obesity threshold, or those using the drug for other conditions such as reducing the risk of serious heart problems.
Patients are still expected to start on a much lower dose of 0.25mg per week, gradually increasing over time under medical supervision until they reach the appropriate level.
For more information on obesity and weight management visit the NHS website
The regulator stressed that patients should only use the medication as prescribed and consult a doctor, pharmacist or nurse if they are unsure about their treatment.
As with all medicines, safety will continue to be closely monitored. Anyone experiencing side effects is urged to report them through the MHRA’s Yellow Card scheme.
The latest move comes amid growing demand for NHS weight loss jabs, with drugs like Wegovy increasingly used to tackle obesity and related health risks across the UK.
